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Abstract
Soluble aggregates of amyloid-β (Aβ) have been associated with neuronal and synaptic loss in Alzheimer’s disease
(AD). However, despite significant recent progress, the mechanisms by which these aggregated species contribute
to disease progression are not fully determined. As the analysis of human cerebrospinal fluid (CSF) provides an
accessible window into the molecular changes associated with the disease progression, we characterised soluble
aggregates present in CSF samples from individuals with AD, mild cognitive impairment (MCI) and healthy controls
using a range of sensitive biophysical methods. We used super-resolution imaging and atomic force microscopy to
characterise the size and structure of the aggregates present in CSF and correlate this with their ability to
permeabilise lipid membranes and induce an inflammatory response. We found that these aggregates are
extremely heterogeneous and exist in a range of sizes, varying both structurally and in their mechanisms of toxicity
during the disease progression. A higher proportion of small aggregates of Aβ that can cause membrane
permeabilization are found in MCI CSF; in established AD, a higher proportion of the aggregates were larger and
more prone to elicit a pro-inflammatory response in glial cells, while there was no detectable change in aggregate
concentration. These results show that large aggregates, some longer than 100 nm, are present in the CSF of AD
patients and suggest that different neurotoxic mechanisms are prevalent at different stages of AD.
Keywords: Alzheimer’s disease, Mild cognitive impairment, Cerebrospinal fluid, Protein aggregation, Structure-
function relation, Super-resolution imaging, Disease mechanism
Introduction
Small soluble aggregates of amyloid-β (Aβ) have been
shown to impair hippocampal synaptic plasticity, induce
learning deficits and correlate with cognitive impair-
ments both in Alzheimer’s disease (AD) mouse models
and humans [13, 27, 30, 40]. These soluble aggregates
can exert cellular toxicity via a range of diverse mecha-
nisms, including oxidative stress, disruption of Ca2+
homeostasis and cellular signalling, mitochondrial alter-
ations, glial activation and inflammation [2, 18]. Many of
these processes are the consequence of two fundamental
upstream events induced by soluble aggregates: (i) per-
meabilisation of cell membranes by non-specific binding
[6, 15] and (ii) specific interactions with receptors in cell
membranes [7, 18]. It is also known that the morphology
of protein aggregates can determine the level of their in-
volvement in different biological interactions. Hydropho-
bic protein aggregates more readily interact with
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hydrophobic lipid membranes, while the size and shape
of the aggregates determine the affinity of binding to re-
ceptors [6, 7, 18, 25]. Understanding how the intrinsic
heterogeneity in the size, shape and structure of the ag-
gregates present in the human brain influences their
mechanism of toxicity and how such heterogeneity
changes as AD progresses is crucial in identifying the
molecular pathways that lead to neuronal death.
Most of our current knowledge about the origins
and morphologies of the toxic soluble species in-
volved in neurodegenerative mechanisms is derived
from in vitro studies and animal models. These stud-
ies have shown the presence of soluble aggregates
with large heterogeneity in size (dimer to higher
order multimers), shape (small spherical to fibril like)
and structure (random coil to β-sheet) [2, 40]. During
disease progression, Aβ in the human brain can ag-
gregate into a large number of different forms, con-
sisting of different numbers of peptides, sizes, shapes
and structural configurations, with multiple possible
post-translational modifications and co-aggregating
species. One way to characterise the presence of toxic
aggregates at different clinical stages and its implica-
tion on disease progression is to study these soluble
aggregates present in AD, mild cognitive impairment
(MCI) and healthy control cerebrospinal fluid (CSF),
since this fluid can reflect at least some of the bio-
chemical changes occurring inside the brain. MCI is a
heterogeneous syndrome, which may have many
underlying causes [39]. A proportion of MCI patients
have AD pathology and are at increased risk of devel-
oping AD dementia. MCI can thus be conceptualised
as a prodromal state in the AD continuum - a transi-
tion between normal cognitive aging and AD [5, 39].
In this study, we used the core AD CSF biomarkers
and clinical dementia rating (CDR), which depend on
the cognitive ability of individuals (see Methods), to
distinguish the MCI cases that had Alzheimer’s patho-
logic changes. These biomarkers used are strongly
predictive of the patient having MCI or AD and the
agreement is 89–90% [17]. This is also in good agree-
ment with Positron-emission tomography (PET) im-
aging classification of AD [17]. We have selected MCI
cases based on the low level of Aβ42 (Aβ42 < 600 ng/
L) indicating brain amyloidosis and where the CDR is
0.5. This procedure allowed us to select solely for the
MCI cases with brain amyloidosis [21], which will
henceforth be referred to as MCI. All the healthy
controls are free of MCI and dementia and had a
CDR of 0. Therefore, to understand the nature of sol-
uble aggregates present at different stages of AD and
how they induce cellular toxicity, we studied CSF
samples collected from individuals affected from AD
and MCI and compared these with healthy controls.
CSF is continuously produced, recycled and freely ex-
changed with the interstitial fluid in the brain, making it
an ideal reservoir of soluble aggregates that can be re-
flective of toxic species present in the brain tissue for
that disease stage. It has been demonstrated that soluble
Aβ is secreted into the CSF, making it an ideal bio-
marker candidate for AD [4, 24, 39]. The total mass of
Aβ oligomers and monomers have been measured in
AD CSF using sensitive enzyme-linked immunosorbent
assay (ELISA) based methods [4, 22, 38] . In all experi-
ments there is significant overlap in the total mass of Aβ
oligomers between control and AD patients, although a
small increase in Aβ oligomers mass has been reported
for some cohorts [22, 38]. This suggest that structural
changes in the Aβ oligomers may be more important in
driving disease. However, due to a lack of suitably sensi-
tive methods, the specific detection and quantification of
the heterogeneity in morphology of soluble Aβ aggre-
gates present in CSF have not yet been determined. Un-
derstanding the changes in these soluble aggregates that
occur during disease progression may provide new in-
sights into the disease mechanisms with potential for
early diagnosis.
Materials and methods
Ad CSF
The CSF used for all the assays was collected by lum-
bar puncture from patients who sought medical ad-
vice because of memory problems. The samples were
de-identified and aliquoted into 0.5 mL aliquots in
polypropylene cryo tubes following centrifugation at
2,200 xg in 20 °C for 10 min and stored at − 80 °C
pending experimental use. CSF Aβ1–42, T-tau and P-
tau181 were quantified with sandwich ELISAs
INNOTEST® β-amyloid1–42, hTAU-Ag and Phospho-
Tau [181P], respectively (Additional file 1: Table S1).
All measurements were performed in clinical labora-
tory practice by board-certified laboratory technicians
using procedures approved by the Swedish Board for
Accreditation and Conformity Assessment. Intra-assay
coefficients of variation were below 10%. All AD-
positive samples had protein levels of Aβ42 < 600 ng/
L, T-tau > 350 ng/L and P-tau181 > 80 ng/L. The study
protocol was approved by the regional ethics commit-
tee at the University of Gothenburg.
MCI and control CSF
MCI (6) and control (6) samples were collected from the
Gothenburg H70 Birth Cohort Studies in Gothenburg,
Sweden [24, 37]. These samples were obtained from the
Swedish Population Registry and included both persons
living in private households and in residential care and
approved by the Regional Ethical Review Board in Goth-
enburg. As described previously, lumbar punctures to
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collect CSF samples were performed in the L3/L4 or L4/
L5 inter-space in the morning [3]. The first 10 mL of
CSF were collected in a polypropylene tube and immedi-
ately transported to the laboratory for centrifugation at
1,800 xg in 20 °C for 10 min and stored at − 80 °C pend-
ing experimental use.. The supernatant was gently mixed
to avoid possible gradient effects, aliquoted in polypro-
pylene tubes and stored at − 70 °C [3]. CSF Aβ42, T-tau
and P-tau181 were quantified with sandwich ELISAs
INNOTEST® β-amyloid1–42, hTAU-Ag and Phospho-Tau
[181P], respectively.
As previously published, every 70-year-old in Goth-
enburg, Sweden, born during 1944 on prespecified
birthdates was invited to the examination in 2014–
2016, and 1203 participated (response rate 72.2%). Of
these, 430 (35.8%) consented to a lumbar puncture
[24]. Participants were examined at the Neuropsychi-
atric memory clinic at Sahlgrenska University Hospital
in Gothenburg or at home. Experienced psychiatric
research nurses performed the neuropsychiatric exam-
inations, which comprised ratings of psychiatric symp-
toms and signs, tests of mental functioning, including
assessments of episodic memory (short-term, long-
term), aphasia, apraxia, agnosia, executive functioning
and personality changes. Key informant interviews
were performed by psychiatric research nurses as de-
scribed previously [24, 37]. Examinations included the
Mini Mental State Examination and the clinical de-
mentia rating (CDR). Dementia was diagnosed accord-
ing to the DSM-III-R criteria.
For each participant, the clinical MCI diagnosis was
determined in a clinical consensus conference, com-
prised of a neurologist and psychiatrist, taking into
account the participants history and information from
informants. CSF biomarker levels of Aβ 42, total-tau
and Phopho-tau were considered in choosing partici-
pants with MCI and underlying preclinical AD path-
ology. All MCI participants had a clinical dementia
rating (CDR) score of 0.5. Healthy controls had to be
free of MCI and Dementia and had a CDR of 0. De-
mentia diagnoses were an exclusion criterion in this
study.
All samples were collected in the morning (before
lunch) at the highly coordinated memory clinics in
south-western Sweden, using clinically implemented
CSF sampling protocol that has been detailed in: Blen-
now et al. [5]. All samples were stored in Gothenburg
with only one freeze-thaw cycle.
Membrane permeabilisation assay
A detailed protocol and further description of the
membrane permeabilisation can be found elsewhere
[14]. Briefly, 200 nm mean diameter vesicles com-
posed of 16:0–18:1 PC and 18:1–12:0 biotin PC (100:
1) (Avanti Lipids) were prepared using extrusion and
freeze-thaw cycles. Vesicles were filled with 100 μM
of Cal-520 dye and tethered in the glass surface via
biotin-neutravidin linkage. A glass surface was coated
using PLL-g-PEG and PLL-g-PEG biotin (10:1) (Susos
AG). To measure the background for each set, 9 dif-
ferent images were acquired in the presence of only
30 μL Ca2+ containing buffer, which we denote as
blank (Fblank). Then a 30 μL CSF aliquot was added to
the glass coverslip and incubated for 15 min before
images of the exact same fields of view were recorded
(Fsample). Then, 10 μL of ionomycin was added to the
same coverslip and images of the vesicles were ac-
quired in the same fields of view (Fionomycin). The re-
corded images were analysed to determine the
fluorescence intensity of each vesicle under the three
different conditions and the average Ca2+ influx for
each vesicle was calculated using the formula (Fsample
- Fblank) / (Fionomycin - Fblank) X 100%. The stage
movements were performed using a bean shell-based
program which allows to select fields of view without
any user bias. For antibody experiment, CSF and 300
nM antibody were incubated for 15 min and added to
the vesicle containing glass coverslip for membrane
permeabilisation study.
Imaging of individual vesicles were performed using a
home-built total internal reflection fluorescence (TIRF)
microscope. For excitation, a 488 nm laser (Toptica)
beam was focussed in the back focal plane of the 60x,
1.49 NA oil-immersion objective lens (APON60XO
TIRF, Olympus, N2709400). Fluorescence emission from
the dyes were collected by the same objective and im-
aged onto an air-cooled EmCCD camera (Photometrics
Evolve, EVO-512-M-FW- 16-AC-110).
Inflammation assay
The BV2 cell line was derived from immortalised
murine neonatal microglia and grown in 10% foetal
bovine serum and 1% L-Glutamine supplemented
Dulbecco’s Modified Eagle’s (DMEM) medium. The
cells were incubated at 37 °C in a humidified atmos-
phere of 5% CO2 and 95% air, until the cell density
reached approximately 1.6 × 106 cell/mL. 200 μL of
CSF was diluted in 1 mL of DMEM and added to
BV2 microglia cells. Every 24 h the supernatant was
removed for analysis and replaced by fresh diluted
CSF. The TNF-α concentration in the supernatant
was quantified using the Duoset® enzyme-linked im-
munosorbent assay (ELISA) development system
(R&D Systems, Abingdon, Oxfordshire, UK). Three
wells for each CSF were used to estimate variation in
the experiments. For antibody experiment, CSF and
antibody were diluted in DMEM buffer and added to
the vesicle containing glass coverslip.
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Aptamer-DNA PAINT (AD PAINT) imaging
AD PAINT was performed as described previously22.
Briefly, glass-slides were cleaned with argon plasma,
rinsed with 1% tween-20 and washed with PBS. All
buffers were first passed through a 0.02 μm filter
(Anotop25, Whatman). The CSF was diluted ten-fold
in PBS and added to wells on the coverslip formed by
a multiwell chamber coverslip (CultureWell CWCS-
50R-1.0). After leaving any aggregates to adhere to
the surface for 5 min the CSF was removed, the wells
were washed with PBS and then filled with imaging
mix (1 nM imaging strand (sequence CCAGATGTAT-
CY3B) and 100 nM aptamer-docking strand (sequence
GCCTGTGGTGTTGGGGCGGGTGCGTTATACAT
CTA) in PBS). The wells were then sealed using an-
other clean coverslip. The samples were imaged on a
home-built TIRF microscope using a 1.49 N.A., 60x
TIRF objective (UPLSAPO, 60X, TIRF, Olympus)
mounted on a Ti-E Eclipse microscope (Nikon) fitted
with a perfect focus system. The Cy3B was excited at
561 nm (Cobalt Jive, Cobalt) passed through a FF01–
561/14–25 excitation filter (Semrock). Fluorescence
was separated from the excitation light using a di-
chroic mirror (Di01-R405/488/561/635, Semrock),
passed through a filter (LP02-568RS-25, Semrock)
and focussed on the EMCCD camera described above
operating in frame transfer mode (electron-multiply-
ing Gain of 11.5 e-1/ADU and 250 ADU/photon). To
eliminate user bias an automated script (Micro-Man-
ager [12]) was used to collect images in a grid. Five
thousand frames were collected with an exposure
time of 50 ms. Images were analysed using the Peak
Fit ImageJ plugin of the GDSC Single Molecule Light
Microscopy package and custom scripts written in Py-
thon. The data analysis is described in detail in
Whiten et al [43].
Atomic force microscopy imaging
CSFs are diluted 10x using PBS buffer and image on
freshly cleaved mica substrates using AFM. 10 μL diluted
CSF samples were deposited on the substrate at room
temperature. The samples were incubated for 10 min
and followed by rinsing with 1mL milli Q water. Then
the samples were dried using a gentle flow of nitrogen
gas. AFM maps were created using a NX10 (Park Sys-
tems, South Korea) and JPK nanowizard2 system (JPK
Instruments, Germany) operating in non-contact mode.
This set-up equipped with a silicon tip with a nominal
radius of < 10 nm. Scanning Probe Image Processor
(SPIP) (Image Metrology, Denmark) software were used
for image flattening and single aggregate statistical ana-
lysis. The lateral resolution of this technique is deter-
mined by the geometry of the AFM tip, although the
measurement of the height of individual species is not
significantly affect by the tip geometry. The average level
of noise for each image was measured using SPIP soft-
ware and is well below 0.1 nm. The signal to noise ratio
for measuring a single Aβ42 monomer is close to 10.
Thus, the characterisation of cross-sectional height can
be performed with high sensitivity and accuracy.
Confocal imaging of CSF using pentameric formyl
thiophene acetic acid (pFTAA)
Single-molecule confocal experiments were per-
formed using the previously-reported method [41].
CSF samples were diluted 1:1 into pentameric formyl
thiophene acetic acid (pFTAA) solution (60 μM, PBS)
and withdrawn through a single-channel microfluidic
device at a flow velocity of 0.56 cm·s− 1. A 488 nm
laser beam (1.5~mW, Spectra Physics Cyan CDRH)
was directed to the back aperture of an inverted
microscope (Nikon Eclipse TE2000-U). The beam
was reflected by a dichroic mirror (51008BS,
Chrome) and focussed to a concentric diffraction-
limited spot, 10 μm into the solutions in the micro-
fluidic channel through a high numerical aperture oil
immersion objective (Apochromat 60X, NA 1.40,
Nikon). Fluorescence was collected using the same
objective, passing through the same dichroic mirror
and imaged onto a 50 μm pinhole (Melles Griot) to
remove out-of-focus light. The emission was filtered
(535AF45, Omega) and directed to an avalanche
photodiode (APD, SPCM-14, Perkin-Elmer Optoelec-
tronics). A custom-programmed field-programmable
gate array, FPGA (Colexica), was used to count the
signals from the APD and combine these into time-
bins which were selected according to the expected
residence time of molecules passing through the
confocal probe volume. At each time-point data were
collected for 10 min (100000-time bins, bin-width
0.2~ms). The experimental output data were col-
lected using an FPGA card and analysed in Python
using custom-written code. A threshold of back-
ground + 20 was set for all measurements so as to
maximise the number of events, whilst removing the
noise.
Production and purification of antibodies
The Aβ-specific nanobody Nb3 was isolated from a
llama (Llama glama) and amplified from the periph-
eral blood lymphocytes, as described previously [11].
The concentration was estimated by absorbance spec-
troscopy at 280 nM using a molecular extinction coef-
ficient, which was calculated based on the sequence
of the protein of 21,555M− 1 cm− 1. Nb3 binds to the
epitope 17–28 of Aβ with a measured Kd for the
monomer of 13 nM [32] .
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Rationally designed antibodies to Aβ42 were generated
as previously described [1, 10]. These antibodies are de-
signed to preferentially bind the target epitope when the
protein is in the aggregated rather than in the mono-
meric conformation. Briefly, complementary peptides
were selected using the cascade method to target linear
epitopes within Aβ42 that scan its entire sequence.
These complementary peptides were then grafted into
the complementarity determining region 3 of an anti-
body scaffold by means of a mutagenic polymerase chain
reaction with phosphorylated oligonucleotides. The
DesAb variants were overexpressed and purified using
pRSET-B vector in E. coli BL21 (DE3) Gold Strain. Over-
night Express Instant TB Medium (Merck Millipore)
supplemented with 100 μg/ml ampicillin were used as a
medium for cell growing. Then it was harvested by cen-
trifugation; resuspended in phosphate-buffered saline
(PBS), then one tablet of EDTA-Free Complete Protease
Inhibitor Cocktail (Roche) was added to 500 mL of cell
growth media. Then cells are lysed by sonication and
debris was removed by centrifugation at 15,000 rpm (JA-
20 rotor, Beckman Coulter). The cleaned lysate was
loaded onto a Ni2+ −NTA Superflow column (Qiagen)
using PBS with 10 mM imidazole. Then His-tagged
DesAbs were eluted with PBS containing 200 mM imid-
azole and lastly the. Imidazole was then removed using
size exclusion chromatography. Protein concentration
was determined by absorbance measurement at 280 nm
using theoretical extinction coefficients and calculated
with ExPASy ProtParam. Previous experiments have
confirmed that the rationally designed antibodies bind to
their target epitopes. The affinity for monomeric Aβ is
in the range 200 to 900 nM, while the affinity for Aβ ag-
gregates is in the range 1–10 nM [1, 10].
Statistical tests
To assess the statistical significance of the difference
among AD, MCI and control CSF for membrane
permeability assay, we performed a two-sample t-test
(unpaired) (Fig. 1b) using origin 9.0. We also used
the same two-sample t-test (unpaired) assay to check
if the antibodies significantly inhibit CSF-induced
membrane permeabilisation (n = 3) (Fig. 2b. and
Additional file 1: Figure S2). To determine the statis-
tical significance of the results on the inflammatory
response induced by AD, control and MCI CSF sam-
ples (Fig. 1d) and on the antibody-induced inhibition
of the toxicity of AD CSF samples we also per-
formed two-sample t-test (unpaired) at 96 h (n = 3)
(Fig. 2a). The number of aggregates present in the
CSF samples was tested using a one-way ANOVA
with Tukey’s Multiple Comparison post-test (Fig. 3b
and Additional file 1: Figure S1). Significance in the
differences of the size distributions of the aggregates
were evaluated using the Kolmogorov-Smirnov test
(Fig. 3f, g).
Results and discussions
Soluble aggregates present in AD and MCI CSF induce
toxicity by distinct mechanisms
We used CSF from individuals diagnosed with MCI,
AD as well as healthy controls to perform a series of
proof of concept experiments on a small set of clin-
ical samples of CSF to explore if our assays could de-
tect differences between the aggregates present in
CSF at different stages of AD. We first set out to
analyse the toxicity of the soluble aggregates in CSF
by measuring their ability to permeabilise lipid mem-
branes and induce an inflammatory response. As the
non-specific binding of protein aggregates to lipid
membranes is driven in particular by hydrophobic in-
teractions, aggregates with more hydrophobic patches
show increased toxicity via disruption and permeabil-
isation of the lipid membrane. To quantitatively
measure how the soluble aggregates act in this man-
ner, we used a recently developed biophysical assay,
which has shown that physiological concentrations of
soluble aggregates of Aβ can destabilise lipid mem-
branes [9, 14]. For this assay, we immobilised thou-
sands of single POPC vesicles (mean diameter - 200
nm) containing the Ca2+-specific dye, Cal-520, onto
PEGylated glass cover slides via biotin-neutravidin
linkage. When CSF samples are added, soluble aggre-
gates present permeabilise the membrane of lipid ves-
icles and Ca2+ from the surrounding solution enter
individual vesicles causing a change in the fluores-
cence intensity of the dye (Fig. 1a). The change in
fluorescence intensity in these nano-sized vesicles is
proportional to the number of ions that entered and
can be quantified using TIRF microscopy [14, 20].
Using this sensitive method capable of detecting entry
of a single Ca2+ ion, we found that aliquots of MCI
CSF cause greater membrane permeabilisation com-
pared to the AD and control CSF (Fig. 1b). By con-
trast, we found no significant difference in membrane
permeation induced by AD and control CSF, in agree-
ment with a previously reported study [11].
We instead observed the opposite trend in the
CSF-induced pro-inflammatory response in glial cells
(Fig. 1c). Physiological concentrations of protein
aggregates can interact with specific membrane re-
ceptors in microglial cells and induce a proinflam-
matory response [19]. This response can be
quantified by measuring secreted tumour necrosis
factor alpha (TNF-ɑ), one of the pro-inflammatory
cytokines that is produced, using an ELISA assay. To
sensitively determine if CSF samples can induce a
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proinflammatory response, we added them to BV2
microglia cells and incubated for 5 days. These cells
develop a sensitised response to the aggregates over
time, leading to a detectable increase in TNF-α se-
cretion, as we observed previously with synthetic ag-
gregates of alpha synuclein [19]. Every 24 h, we took
the supernatant above the cells and measured the
TNF-α concentration. We found that over time the
CSF aliquots can activate an innate immune re-
sponse leading to the production of significant
amounts of TNF-α. We observed that AD CSF sam-
ples induced a stronger inflammatory response than
the MCI and control CSF samples (Fig. 1d). This in-
flammatory response induced by AD CSF was sig-
nificantly blocked by Rhodobacter sphaeroides lipid
A (RSLA), a known Toll-like receptor (TLR)-4 an-
tagonist [33] and TAK-242, a small-molecule inhibi-
tor that binds selectively and inhibits signalling of
TLR-4 [23] showing that signalling is mediated by
TLR-4 (Additional file 1: Figure S1).
Soluble amyloid-β aggregates present in AD and MCI CSF
are structurally distinct
We explored the feasibility of performing immunodeple-
tions in CSF, using antibodies on beads, but found that
the non-specific control antibody also reduced the num-
ber of detectable aggregates and the amount of mem-
brane permeabilization to the same extent as the specific
antibody. This was due to the non-specific binding of
the low concentration of aggregates in the CSF to the
hydrophobic beads. Therefore, to gain insight into the
composition of the soluble aggregates responsible for the
observed membrane permeabilisation we used several
antibodies raised against Aβ to determine whether they
could block the CSF-induced toxicity A relatively high
dynamic range is required to perform these experiments
so they were therefore performed on the three MCI and
AD CSF samples that showed the highest level of mem-
brane permeabilization. To this end, we employed a
series of Aβ-specific antibodies which were previously
shown to counteract the toxicity induced by soluble
Fig. 1 Soluble aggregates present in MCI and AD CSF samples show different dominant mechanisms of toxicity. a Membrane permeabilisation
was measured by immobilising hundreds of vesicles containing a Ca2+-sensitive dye on PEGylated glass cover slides. If any species present in the
CSF disrupts the integrity of the lipid membrane of the vesicles, Ca2+ ions from the surrounding buffer enter into individual vesicles in numbers
that can be quantified using highly sensitive TIRF microscopy. b Aliquots of MCI CSF can cause more membrane permeabilisation compared to
AD and control CSF (n = 6 AD, 6 MCI, 6 control CSF). A two-sample unpaired t-test was performed to compare each data set. c The inflammatory
response in microglia cells was quantified using an ELISA assay to measure the levels of secreted tumour necrosis factor alpha (TNF-ɑ). d For this
study, CSF samples were added to BV2 microglia cells and incubated for 120 h. Every 24 h the TNF-α concentration in the supernatant was
quantified using an ELISA assay. AD CSF samples were more effective MCI and control CSF samples in inducing an inflammatory response (lines
are guide to the eye; n = 10 AD, 6 MCI, 6 control CSF). Error bars are the standard deviation among data points. A two-sample unpaired t-test at
the 120 h time point was performed to compare the data sets
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aggregates of Aβ both in vitro and in AD CSF. Firstly we
used an antibody Nb3 which recognises the NAC region
(aa17–24) of the Aβ sequence, and found it was able to
significantly reduce the aggregate-induced membrane
permeabilisation for both AD and MCI (Fig. 2a, b). It
was used at a concentration of 300 nM, 20-fold higher
than its Kd (~ 13 nM) [32]. We also used two different
aggregate specific designed antibodies which were shown
to target regions near the N- and C- termini (aa3–9 and
36–42, respectively) of the Aβ peptide to confirm our
findings [25, 30]. We found that both the antibodies
recognising the N-terminus and C-termini were both ef-
fective at reducing lipid membrane permeation (Fig. 2c),
These results indicate that at least a portion of the toxic
aggregates present in MCI and AD CSF are composed of
Aβ. In contrast, a non-specific control antibody did not
reduce membrane permeabilization Additional file 1:
Figure S2). We also found that the antibody that targets
the N-terminus of Aβ, but not the antibody that targets
the C-terminus, efficiently inhibits an AD CSF-induced
Fig. 2 The toxic soluble aggregates present in MCI and AD CSF contain Aβ. A significant inhibition of the membrane permeabilisation of lipid
membranes by (a) AD and (b) MCI CSF samples is caused by a nanobody Nb3 (300 nM) designed to bind to Aβ, indicating that some of the
aggregates present in MCI and AD CSF contain Aβ. Nb3 recognises amino acids 17–28 of the Aβ sequence and shown to inhibit toxicity induced
by protein aggregates of Aβ cerebrospinal fluid samples from AD patient (c) Both N-terminally and C-terminally targeting antibodies significantly
inhibit MCI CSF-induced membrane permeabilisation. However, we do not find any significant difference between their activities. Error bars are
the standard deviation among data points. Two sample unpaired t-tests were performed to compare the data sets (n = 3). d A N-terminal binding
antibody (binding the region of residues 3–9 of Aβ42) is more potent at reducing the aggregate-induced inflammatory response than a C-
terminal designed antibody (binding the region of residues 36–42 of Aβ42); P values are calculated using a two sample t-test to compare the
inhibition by an N-terminally binding antibody and a C-terminally antibody at 96 h (n = 3). Error bars are the standard deviation among
data points
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Fig. 3 Super-resolution imaging of aggregates present in CSF using AD-PAINT. a Schematic of AD PAINT. Dye-labelled DNA imaging strands
transiently bind to their complementary target sequence (docking strand), which is attached to a protein aggregate via aptamer. This transient
binding between imaging and docking strand is detected. Repeated cycles of binding and unbinding allows a super-resolved image of individual
protein aggregate present in CSF to be determined. The right image shows examples of super-resolved image of protein aggregates from CSF.
Three individual protein aggregates present in CSF are enlarged. The lengths of the aggregates shown are: (i) 47 nm, (ii) 34 nm and (iii) 118 nm. b
Number of aggregates present in control, MCI and AD CSF samples. Each point represents one field of view. c Cumulative frequency histograms
of the size distributions of all aggregates measured. d, e Differences between normalised histograms of the size distributions of the indicated CSF
samples. f, g Differences between the cumulative frequency histograms of the size distributions of the indicated CSF samples. The dotted line
indicates 99% confidence using the Kolmogorov-Smirnov statistical test. (n = 6 AD, 6 MCI, 6 control CSF)
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inflammatory response (Fig. 2d). The differential effects
of N-terminal and C-terminal antibodies provide infor-
mation not only on the composition but also on the
structure of the soluble aggregates present in AD CSF.
Mature fibrillar aggregates have a hydrophobic C-
terminus which is inaccessible to C-terminal antibodies,
while the N-terminus residues of aggregates are exposed
[16, 28, 31]. These results suggest that the aggregates
present in the CSF that are responsible for inducing
membrane permeation are structurally distinct from
those that induce an inflammatory response.
Single aggregate super-resolution imaging shows the
differing size distributions of soluble aggregates present
in AD and MCI CSF
To examine the size and morphology of these soluble
aggregates, we employed a newly developed super-
resolution technique, aptamer DNA PAINT (ADPAINT)
(Fig. 3a) [43]. The small size of the aptamer in combin-
ation with its remarkable specificity and affinity allows
us to resolve aggregated structures of Aβ with a preci-
sion of approximately 20 nm. We have previously dem-
onstrated the utility of this imaging technique by
accurately identifying and nanoscopically characterising
the shapes and sizes of the species formed during an ag-
gregation reaction and in iPSC neurons [43]. Using this
technique, we analysed the average number of aggregates
present in the CSF samples and measured the size of in-
dividual aggregates (Fig. 3b,c), which ranged from 20
nm, limited by our resolution, to 300 nm. We did not
find any significant difference in the total number of ag-
gregated species present among MCI, AD and control
CSF samples (6 each), a result that we confirmed using
the amyloid-specific dye PFTAA (Additional file 1: Fig-
ure S3).
To examine the aggregate morphologies, we plotted
the relative differences between normalised (Fig. 3d,e)
and cumulative (Fig. 3f,g) histograms of the size distribu-
tions of aggregates present in control vs MCI and AD
CSF samples. In the plots of relative differences negative
values indicate that more aggregates of that size are
present in the disease CSF, whereas positive values indi-
cate more aggregates of that size are present in control
CSF. Similarly, a negative slope indicates more aggre-
gates of that size are present in disease CSF when look-
ing at the cumulative differences. We found that, with
99% confidence, the number of small aggregates (< 50
nm) present in MCI CSF was higher than that found in
control CSF (Fig. 3d,f ). This result suggests that a rela-
tively larger number of small aggregates might be
accountable for enhanced membrane permeabilisation
induced by MCI CSF. This finding agrees with previ-
ously reported studies that small sized Aβ aggregates are
more hydrophobic and have greater tendencies to
interact, permeabilise and cross the plasma membrane
[6, 25]. In contrast, a ten-fold larger change was ob-
served in the size distribution of AD CSF compared to
control CSF, with a larger number of longer, mature ag-
gregates (~ 40 to 200 nm) (Fig. 3e,g). Together, these
results, in combination with the AD CSF-induced
inflammation inhibition by an N-terminus antibody
(Fig. 2a) suggest that relatively longer aggregates present
in AD CSF might be responsible for the increased in-
flammatory response. Additionally, these data are also in
agreement with previous reports on synthetic Aβ aggre-
gates, which cannot undergo post-translational modifica-
tions. It was found that Aβ aggregates greater than 100
nm formed in artificial CSF can trigger an inflammatory
response in microglial cells that can be blocked by an
Aβ N-terminal region recognising antibody [8, 31, 42].
We also recently reported results that small aggregates
of Aβ42 which form during the early stages of aggrega-
tion are more potent at membrane permeabilisation,
whereas protofilament aggregates of similar length to
the aggregates detected in CSF with height of 0.4–1 nm,
which form at later stages of aggregation, are more ef-
fective at inducing inflammatory response in murine
glial cells via TLR4 receptor [10]. Thus, the data on syn-
thetic Aβ aggregates also supports the idea that longer
Aβ aggregates in AD CSF cause neuroinflammation.
The increase in the relative proportion of large aggre-
gates means that there is also a small increase in the
total mass of Aβ present in AD CSF, as also previously
detected by ELISAs. However, ELISA cannot measure
the mass and aggregate number independently. This
may explain why it is difficult to detect a clear difference
between control and AD CSF since both factors contrib-
ute to the total aggregate mass detected in a given sam-
ple. This also suggests that the observed reduction in Aβ
monomer concentration in AD CSF is partially due to
this increased mass of aggregates, although this cannot
account for the entire reduction and presumably there is
also significant deposition of aggregates in the brain.
Structural characterisation of soluble aggregates presents
in CSF using high resolution atomic force microscopy
(AFM) at the single aggregate level
To measure the heterogeneity and three-dimensional
morphological properties of the protein aggregates
present in the CSF samples, we utilised a phase con-
trolled AFM technique to resolve the structures of in-
dividual protein aggregates at Angstrom resolution
[35, 36] (Fig. 4). This allowed us to determine the
heights of the individual species present in the CSF.
For these experiments the samples of CSF were dried
directly onto a mica surface. The control CSF sample
showed the uniform presence of abundant spherical
species, whereas both the MCI and AD samples
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Fig. 4 Characterization of the protein aggregates present in CSF samples at single aggregate level using AFM. a-c Representative AFM images of
the aggregates present at different CSF samples with (d-j) a magnified example of the species present. j, k Statistical analysis of the cross-
sectional length and heights of individual aggregates present in CSF samples; the length of the individual aggregates are shown as a box chart
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showed the co-existence of spherical species and
elongated aggregates (Fig. 4). We then performed a
statistical analysis of their cross-sectional length and
heights of individual aggregates [35]. The MCI CSF
sample showed a relatively uniform population of
elongated aggregates with a cross-sectional height
ranging between 0.3–1 nm (Fig. 4b) and length 50–
100 nm (Fig. 4c), larger than the typical length of spe-
cies in the control sample (p < 0.001). The AD CSF
samples showed the coexistence of highly heteroge-
neous elongated aggregates. These species belonged
roughly to two populations of height, the first with
cross sectional height ranging between 0.3–1 nm
which is similar to the species present in MCI CSF
aggregates, often referred to as protofilaments, and
the second with cross-sectional height between 1 and
3 nm, often referred to as protofibrils. A larger cross-
sectional aggregate height has been associated in vitro
to an increased content of intermolecular β-sheet and
maturity of amyloid structure [36]. The AD elongated
aggregates are significantly longer than the MCI CSF
sample (p < 0.001), ranging in length between 50 and
400 nm. This data is highly consistent with the super-
resolution imaging data suggesting that the same spe-
cies are being detected in both experiments. These
data, in conjunction with the AD PAINT data, con-
firm that the protein aggregates present in AD CSF
differ in structure from the aggregates present in
MCI and control CSF. We cannot formally conclude
that these species are Aβ aggregates since the AFM
measurement is composition insensitive. However, we
have shown that a higher proportion of longer aggre-
gates are present in AD CSF and that this correlates
with increased inflammation. Overall these findings
suggest that long Aβ protofiibrils cause the increased
inflammation detected in AD CSF. It has also been
shown that that the protofibrillar aggregate of amyloid
beta can cause the inflammation in murine BV2 cells
[10]. Interestingly and in support of this conclusion,
there is a crystal structure of TLR3, which is in the
same family as TLR4, bound to an RNA dimer which
is about 2 nm in diameter [29]. TLR3 signalling oc-
curs when the RNA dimer is longer than 15 nm [26].
Since the long AD protofibrillar aggregates, have a
cross-sectional height of round 2 nm, this provides a
plausible explanation of how they cause TLR4 signal-
ling in AD CSF.
Conclusions
In conclusion, we have reported that there is a higher pro-
portion of small aggregates that can cause increased mem-
brane permeabilisation present in MCI CSF than in AD
and control CSF, while in AD CSF there is an increased
number of larger and longer aggregates, corresponding
with enhanced neuroinflammation. These larger aggre-
gates appear to be protofibrillar in nature, with distinct
structural features from those of the smaller aggregates
and appear to be the species that initiates cytokine pro-
duction via TLR4 signalling.
It has to be noted that our study has been performed
on a small number of samples and in future work it
would be of interest to see if we observe the same
changes in aggregate size distributions in bigger cohorts.
If replicated then following the changes in aggregate size
distribution provides a method to follow disease pro-
gression that does not require the measurement of the
absolute number of aggregate species, with the propor-
tion of larger aggregates increasing. Our results indicate
that as the disease progresses there are changes in the
aggregate size distribution in CSF but not in the total
number of species. It has been reported that there is a
three-fold increase in Aβ aggregates deposited in the
brain during the development of AD [34]. Taken to-
gether this suggests that there is a change in both aggre-
gate number and size distribution in the brain during
the development of AD, but only the change in aggre-
gate size distribution is detectable in the CSF sampled in
a lumber puncture. This change in aggregate size distri-
bution may be important in the disease mechanism since
it corresponds with a change in aggregate structure and
changes the dominant mechanism of aggregate-induced
cellular toxicity. This in turn suggests that a combin-
ation of therapeutic agents targeting aggregated species
with varying size and morphology, rather than a single
agent targeting a single structure of one toxic form of
Aβ may be needed to develop effective treatments for
AD. Lastly, our data shows that sensitive biophysical
methods are now capable of characterising the aggre-
gates present in human CSF at new levels of detail, pro-
viding an opportunity to determine what changes in
aggregate size and structure correlate with different
stages of disease and new information about the species
that initiate and drive the development of AD.
Additional file
Additional file 1: Table S1. Characterisation of the CSF samples used in
this study. Figure S1 Toll like receptor 4 (TLR4) antagonists block AD CSF-
induced aggregate induced inflammation. Figure S2 a portion of the toxic
aggregates present in MCI and AD CSF are composed of Aβ To understand
the composition of toxic aggregate present in human CSF. we employed a
series of Aβ-specific antibody which are known to counteract the toxicity
induced by soluble aggregates of Aβ. Figure S3 Detection of aggregates
present in control, MCI and AD CSF using pFTAA. (DOCX 197 kb)
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